IFCC Interim Guidelines on Biochemical/Hematological Monitoring of COVID-19 Patients

Clin Chem Lab Med. 2020 Oct 7;58(12):2009-2016. doi: 10.1515/cclm-2020-1414.

Abstract

Routine biochemical and hematological tests have been reported to be useful in the stratification and prognostication of pediatric and adult patients with diagnosed coronavirus disease (COVID-19), correlating with poor outcomes such as the need for mechanical ventilation or intensive care, progression to multisystem organ failure, and/or death. While these tests are already well established in most clinical laboratories, there is still debate regarding their clinical value in the management of COVID-19, particularly in pediatrics, as well as the value of composite clinical risk scores in COVID-19 prognostication. This document by the International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 provides interim guidance on: (A) clinical indications for testing, (B) recommendations for test selection and interpretation, (C) considerations in test interpretation, and (D) current limitations of biochemical/hematological monitoring of COVID-19 patients. These evidence-based recommendations will provide practical guidance to clinical laboratories worldwide, underscoring the contribution of biochemical and hematological testing to our collective pandemic response.

Keywords: COVID-19; SARS-CoV-2; biochemistry; hematology.

MeSH terms

  • Adult
  • Biomarkers / blood
  • Cardiovascular Diseases / complications
  • Child
  • Coronavirus Infections / blood
  • Coronavirus Infections / complications
  • Coronavirus Infections / metabolism*
  • Female
  • Hematologic Tests*
  • Humans
  • International Agencies*
  • Male
  • Multiple Organ Failure / complications
  • Pandemics
  • Pneumonia, Viral / blood
  • Pneumonia, Viral / complications
  • Pneumonia, Viral / metabolism*
  • Practice Guidelines as Topic*

Substances

  • Biomarkers

Supplementary concepts

  • COVID-19